Novartis discloses seven more Zolgensma tumor cases

· Health · Switzerland · United States

Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, its gene therapy for spinal muscular atrophy, bringing the total to nine recipients. In two of the cases there was evidence that the AAV viral delivery tool integrated into patient DNA, according to BioPharma Dive and STAT. The disclosure raises new questions for the gene therapy field, since AAV vectors underpin many approved and experimental treatments; for SMA patients and their families, it complicates the risk-benefit picture of a therapy already used in young children.

Why it matters：AAV vectors are the backbone of much of the gene therapy pipeline, so evidence of insertional tumor risk could affect regulators, developers and patients well beyond Zolgensma.

Key points

  • Nine Zolgensma recipients have now been reported with tumors.
  • Two cases showed evidence of AAV integration into patient DNA.
  • The news follows questions about the durability and safety of AAV-based treatments.

Sources (original reporting)

More stories from this day